1041 related articles for article (PubMed ID: 16938404)
1. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
[TBL] [Abstract][Full Text] [Related]
2. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
Arendash GW; Mori T; Cao C; Mamcarz M; Runfeldt M; Dickson A; Rezai-Zadeh K; Tane J; Citron BA; Lin X; Echeverria V; Potter H
J Alzheimers Dis; 2009; 17(3):661-80. PubMed ID: 19581722
[TBL] [Abstract][Full Text] [Related]
3. Caffeine and coffee as therapeutics against Alzheimer's disease.
Arendash GW; Cao C
J Alzheimers Dis; 2010; 20 Suppl 1():S117-26. PubMed ID: 20182037
[TBL] [Abstract][Full Text] [Related]
4. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Olcese JM; Cao C; Mori T; Mamcarz MB; Maxwell A; Runfeldt MJ; Wang L; Zhang C; Lin X; Zhang G; Arendash GW
J Pineal Res; 2009 Aug; 47(1):82-96. PubMed ID: 19538338
[TBL] [Abstract][Full Text] [Related]
5. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
Arendash GW; Jensen MT; Salem N; Hussein N; Cracchiolo J; Dickson A; Leighty R; Potter H
Neuroscience; 2007 Oct; 149(2):286-302. PubMed ID: 17904756
[TBL] [Abstract][Full Text] [Related]
6. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
Dall'Igna OP; Fett P; Gomes MW; Souza DO; Cunha RA; Lara DR
Exp Neurol; 2007 Jan; 203(1):241-5. PubMed ID: 17007839
[TBL] [Abstract][Full Text] [Related]
7. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice.
Cao C; Wang L; Lin X; Mamcarz M; Zhang C; Bai G; Nong J; Sussman S; Arendash G
J Alzheimers Dis; 2011; 25(2):323-35. PubMed ID: 21422521
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
[TBL] [Abstract][Full Text] [Related]
9. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
Rezai-Zadeh K; Arendash GW; Hou H; Fernandez F; Jensen M; Runfeldt M; Shytle RD; Tan J
Brain Res; 2008 Jun; 1214():177-87. PubMed ID: 18457818
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
11. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
12. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC
J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404
[TBL] [Abstract][Full Text] [Related]
14. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
16. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
[TBL] [Abstract][Full Text] [Related]
17. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
[TBL] [Abstract][Full Text] [Related]
18. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.
Costa DA; Cracchiolo JR; Bachstetter AD; Hughes TF; Bales KR; Paul SM; Mervis RF; Arendash GW; Potter H
Neurobiol Aging; 2007 Jun; 28(6):831-44. PubMed ID: 16730391
[TBL] [Abstract][Full Text] [Related]
19. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
Pan X; Gong N; Zhao J; Yu Z; Gu F; Chen J; Sun X; Zhao L; Yu M; Xu Z; Dong W; Qin Y; Fei G; Zhong C; Xu TL
Brain; 2010 May; 133(Pt 5):1342-51. PubMed ID: 20385653
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease.
Hashimoto T; Ogino K; Shin RW; Kitamoto T; Kikuchi T; Shimizu N
Neurosci Lett; 2010 Jan; 469(2):273-7. PubMed ID: 20025930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
